| Date | e: 4. marts 2022 | | |
|--|---|---|--|
| You | r name: Andreas Ronit | | |
| Mar | nuscript title: Lokal in | mmunpatologi ved COVID-19 | 9 ARDS: patogenese og metodiske overvejelser |
| Mar | nuscript number (if known) |): | |
| are re third comr list a The f manu | elated to the content of yo parties whose interests manitment to transparency are relationship/activity/interests of collowing questions apply to ascript only. | ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that you the author's relationship rities/interests should be one of the author. | relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. Disclosive relate to the current defined broadly. For example, if your manuscript declare all relationships with manufacturers of |
| In ite | | port for the work reported disclosure is the past 36 r | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| Time | e frame: Since the initial plan | ning of the work | |
| 1 | All support for the present | None Non | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, medical writing, | | |
| | article processing charges, etc.) No time limit for this item. | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | Click TAB in last row to add extra rows |
| Time | e frame: past 36 months | | |
| | 1 | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| | | | |
| | | | |
| 3 | Royalties or licenses | | |
| | · | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|---|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

| Date | e: 4. marts 2022 | | |
|--|---|--|--|
| You | r name: Trine H. Mogens | sen | |
| Mai | nuscript title: Lokal in | mmunpatologi ved COVID-19 | 9 ARDS: patogenese og metodiske overvejelser |
| Mar | nuscript number (if known) |): | |
| are re third comr list a The f | elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere | ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo | relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current |
| perta antih In ite | nins to the epidemiology of ypertensive medication, ev | hypertension, you should yen if that medication is n port for the work reported | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months. |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| Time | e frame: Since the initial plan | ning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this | ⊠ None | |
| | item. | | |
| | | | Click TAB in last row to add extra rows |
| Time | e frame: past 36 months | | |
| | | | |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | | |
| | | | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|---|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

| Date | e: 4. marts 2022 | | |
|---|--|---|--|
| You | r name: Ronni R. Plovsin | ng | |
| Mar | nuscript title: Lokal ii | mmunpatologi ved COVID-1 | 9 ARDS: patogenese og metodiske overvejelser |
| Mar | nuscript number (if known |): | |
| are rethird comrist a The finant The aperta antih | elated to the content of yo parties whose interests manitment to transparency and relationship/activity/interestionship questions apply to uscript only. Buthor's relationships/activity interesting to the epidemiology of the e | ur manuscript. "Related" ay be affected by the conduction does not necessarily in est, it is preferable that you the author's relationship rities/interests should be given if that medication is not port for the work reported." | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. |
| Other | interns, the time frame for | disclosure is the past 30 i | nontris. |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| Time | e frame: Since the initial plan | ning of the work | |
| 1 | All support for the present | None Non | |
| | manuscript (e.g., funding, provision of study | | |
| | materials, medical writing, | | |
| | materials, medical writing, | | |
| | article processing charges, | | |
| | | | |
| | article processing charges, | | |
| | article processing charges, etc.) | | |
| | article processing charges, etc.) No time limit for this | | Click TAB in last row to add extra rows |
| Time | article processing charges, etc.) No time limit for this item. | | Click TAB in last row to add extra rows |
| Time | article processing charges, etc.) No time limit for this | | Click TAB in last row to add extra rows |
| Time 2 | article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from | None | Click TAB in last row to add extra rows |
| | article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated | None | Click TAB in last row to add extra rows |
| | article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from | None | Click TAB in last row to add extra rows |
| | article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated | None None None None None | Click TAB in last row to add extra rows |
| 2 | article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above). | | Click TAB in last row to add extra rows |

| 4 | Consulting fees | ⊠ None |
|----|---|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

| Dat | e: 4. marts 2022 | | |
|--|--|---|---|
| You | r name: Ronan M.G. Ber | g | |
| Mai | nuscript title: Lokal in | mmunpatologi ved COVID-19 | 9 ARDS: patogenese og metodiske overvejelser |
| Mar | nuscript number (if known) |): | |
| are re third comr list a The f | elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere | ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo | relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. OS/activities/interests as they relate to the current |
| perta antih In ite | ins to the epidemiology of ypertensive medication, ev | hypertension, you should yen if that medication is n port for the work reported | defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months. |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| Time | e frame: Since the initial plan | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ⊠ None | |
| | No time limit for this item. | | |
| | | | Click TAB in last row to add extra rows |
| Time | e frame: past 36 months | | |
| | | | |
| 2 | Grants or contracts from any entity (if not indicated | None | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None Non | |
| | , | LI NOTIO | |
| | | | |

| 4 | Consulting fees | ⊠ None |
|----|---|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ⊠ None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | ⊠ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal